There are 2949 resources available
LBA20 - Vandetanib plus fulvestrant versus placebo plus fulvestrant after relapse or progression on an aromatase inhibitor in metastatic ER positive breast cancer (FURVA): A randomised, double-blind, placebo-controlled, phase II trial
Presenter: Robert Jones
Session: Mini Oral - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
1022MO - Clinical potential of adoptive cell therapy with tumour infiltrating lymphocytes therapy in combination with checkpoint inhibitors in non-melanoma patients
Presenter: Anders Kverneland
Session: Mini Oral - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
4MO - A novel AI solution for auto-segmentation of multi-origin liver neoplasms
Presenter: Akshayaa Vaidyanathan
Session: Mini Oral - Basic Science
Resources:
Abstract
Slides
Webcast
5MO - Prospective validation of a radiomics signature for chemoradiotherapy lung cancer patients
Presenter: Ralph Leijenaar
Session: Mini Oral - Basic Science
Resources:
Abstract
Slides
Webcast
815MO - The impact of chemosensitivity assessed by modeled CA-125 KELIM on the likelihood of long progression-free survivorship (PS) after 1st line treatment in ovarian cancer: An analysis of 4,450 patients
Presenter: Benoit You
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
816MO - AGO DESKTOP III/ENGOT OV20: Impact of surgical characteristics and time to first subsequent therapy (TFST)
Presenter: Fabrice Lecuru
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
LBA34 - Single-agent anti-PD-1 balstilimab or in combination with anti-CTLA-4 zalifrelimab for recurrent/metastatic (R/M) cervical cancer (CC): Preliminary results of two independent phase II trials
Presenter: David O'Malley
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
LBA35 - Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer
Presenter: Panagiotis Konstantinopoulos
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
LBA36 - Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
Presenter: Ana Oaknin
Session: Mini Oral - Gynaecological cancers 2
Resources:
Abstract
Slides
Webcast
1674MO - ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: Implications for SARS-CoV-2
Presenter: Riyue Bao
Session: Mini Oral - SARS-CoV-2 and cancer 2
Resources:
Abstract
Slides
Webcast